Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 50

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2018

Summary

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Caspase-6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer's Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

The latest report Caspase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)

- The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects

- The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Overview
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Companies Involved in Therapeutics Development
Conatus Pharmaceuticals Inc
New World Laboratories Inc
Novartis AG
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Drug Profiles
ED-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-7314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NWL-154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Dormant Products
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Product Development Milestones
Featured News & Press Releases
Apr 30, 2018: Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension
Apr 18, 2018: Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
Apr 09, 2018: Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Conatus Pharmaceuticals Inc, H1 2018
Pipeline by New World Laboratories Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Soft Gelatin Capsules Market Data Survey Report 2025
    Published: 10-Nov-2018        Price: US 1500 Onwards        Pages: 87
    Summary The global Soft Gelatin Capsules market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing sites, capaci......
  • Global Tissue Engineered Bone Market Research Report 2018
    Published: 09-Nov-2018        Price: US 2900 Onwards        Pages: 113
    This report studies the global Tissue Engineered Bone market status and forecast, categorizes the global Tissue Engineered Bone market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Johnson & Johnson - Stryker - Zimmer Biomet - Medtronic......
  • Global Balsalazide Market Insights, Forecast to 2025
    Published: 09-Nov-2018        Price: US 3900 Onwards        Pages: 117
    Balsalazide is an oral anti-inflammatory drug that is used for the treatment of ulcerative colitis. In 2017, the global Balsalazide market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Balsalazide market based on company, product type, application and key regions. This report studies the global market size of Balsalazide in key regions li......
  • Global Biperiden Market Insights, Forecast to 2025
    Published: 09-Nov-2018        Price: US 3900 Onwards        Pages: 117
    This report studies the global market size of Biperiden in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biperiden in these regions. This research report categorizes the global Biperiden market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, ......
  • Global Botulinum Neurotoxins Market Insights, Forecast to 2025
    Published: 09-Nov-2018        Price: US 3900 Onwards        Pages: 148
    This report studies the global market size of Botulinum Neurotoxins in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Botulinum Neurotoxins in these regions. This research report categorizes the global Botulinum Neurotoxins market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market dri......
  • Global Human Fibrinogen Concentrate Market Research Report 2018
    Published: 09-Nov-2018        Price: US 2900 Onwards        Pages: 111
    This report studies the global Human Fibrinogen Concentrate market status and forecast, categorizes the global Human Fibrinogen Concentrate market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - CSL Behring - LFB Group - Shanghai RAAS - Hua......
  • Global Acetohydroxamic Acid Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 09-Nov-2018        Price: US 3480 Onwards        Pages: 119
    Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a drug that is a potent and irreversible enzyme inhibitor of the urease enzyme in various bacteria and plants; it is usually used for urinary tract infections. Scope of the Report: The elderly population in itself is a large number for urinary tract infections and hence, a high demand for acetohydroxamic acid. The worldwide market for Acetohydroxamic Acid is expected to grow at......
  • Global Influenza Drugs Market Research Report 2018
    Published: 09-Nov-2018        Price: US 2900 Onwards        Pages: 121
    This report studies the global Influenza Drugs market status and forecast, categorizes the global Influenza Drugs market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Bristol-Myers Squibb] - AstraZeneca - Eli Lilly - Roche - GlaxoS......
  • Global Conjugated Estrogen Market Insights, Forecast to 2025
    Published: 09-Nov-2018        Price: US 3900 Onwards        Pages: 113
    Conjugated estrogen is an active pharmaceutical ingredient that contains a mixture of steroidal and non-steroidal components that are obtained from pregnant mares' urine. Conjugated estrogen is used as an external source and is prescribed as a replacement of female natural hormones. Menopause is a natural and normal process in women, which occurs due to aging and lowers the function of ovaries and lowers the levels of estrogen and other hormones in the body. The growing prevalence of the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs